PharmaCielo Ltd. announced that it has received its first commercial purchase order for API from Ease Labs Pharma ("Ease Labs"), a multinational, GMP certified pharmaceutical company headquartered in Brazil. PharmaCielo and Ease Labs have signed an ongoing sales agreement, whereby PharmaCielo will provide Ease Labs regular shipments of CBD Isolate as an API, beginning in February 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.155 CAD | -3.12% | -11.43% | -13.89% |
1st Jan change | Capi. | |
---|---|---|
-13.89% | 19.26M | |
+40.09% | 6.16B | |
-16.34% | 4.46B | |
-7.11% | 3.27B | |
+5.14% | 3.2B | |
-0.18% | 2.6B | |
+47.93% | 1.98B | |
-7.15% | 1.7B | |
+0.67% | 1.66B | |
-8.73% | 1.61B |
- Stock Market
- Equities
- PCLO Stock
- News PharmaCielo Ltd.
- PharmaCielo Receives First Commercial Purchase Order from Ease Labs Pharma